Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Nvidia to buy Israeli AI company for estimated $700M
Xi Focus: Xi Stresses Striving in Unity to Fulfill Goals Set by Party Congress
Xi Focus: Xi Steers Import Expo into Global Platform for Sharing Chinese Opportunities
Who is Humza Yousaf's wife Nadia El
Xi Sends Congratulations to Gala Dinner of National Committee on U.S.
Xi Awards Friendship Medal to Vietnam's Communist Party Chief
Xinhua Headlines: Xi, Biden Hold Candid, In
A third of foreign students seeking to stay in the UK are at just SIX institutions, figures show
Xi Meets Senegalese President Sall